Insulin Glulisine

CAS 207748-29-6 1 FDA-DMF supplierBiologic

Overview

Insulin Glulisine is a rapid-acting insulin analog used to improve blood sugar control in adults and children with diabetes mellitus. It is designed for subcutaneous administration and has a faster onset and shorter duration of action compared to regular human insulin.

Therapeutic areas

Diabetes

Related APIs

Sitagliptin
50 suppliers
Semaglutide
48 suppliers
Empagliflozin
42 suppliers
Metformin
28 suppliers
Canagliflozin
23 suppliers
Dapagliflozin
22 suppliers
Glimepiride
19 suppliers
Repaglinide
18 suppliers

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.

Start free trialBook a demo